AMPK and mTOR also may employ metabolic pathways during the control of severe acute respiratory syndrome coronavirus (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) (Abu-Eid and Ward, 2021[1]; Alves et al., 2022[7]; Bramante et al., 2023[21]; Khan, 2021[119]; Khan et al., 2021[120]; Liu et al., 2023[153]; Maiese, 2020[201][182], 2021[202], 2022[157], 2023[158]; Pinchera et al., 2022[250]; Swain et al., 2021[297]) (Figure 1(Fig. 1)). The gene discussed is MTOR; the disease is COVID-19.